endpts.com/exclusive-two-…

We are thrilled to have led NOETIK's $14M seed round--huge congrats to Ron Alfa, Jacob Rinaldi, and the whole team! More from DCVC General Partner James Hardiman on Noetik's AI-based novel approach to cancer: 👇 dcvc.com/news-insights/…

Excited for NOETIK to unveil its AI platform to fix the broken funnel in cancer drug research and that DCVC led their Seed! Huge congrats to CEO Ron Alfa (Recursion founding team) & CSO Jacob Rinaldi, & James Hardiman who led for us. endpts.com/exclusive-two-…

NOETIK is proud to partner with DCVC as our lead investor on our mission to use AI to develop precision cancer immunotherapies. dcvc.com/news-insights/…

By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing. ow.ly/swtB104Tzkp

Excited to finally be able to talk about what Ron Alfa, Jacob Rinaldi, and the whole NOETIK team have been working on Spatial biology + AI = better cancer therapies, faster More here: dcvc.com/news-insights/…

Thank you Frank Vinluan for the great coverage of @noetik_ai launch in MedCity News.

Thank you Genetic Engineering & Biotechnology News Julianna LeMieux for this great piece with Ron Alfa on @noetik_ai mission. genengnews.com/topics/drug-di…

#SpatialBiology and #AI Combined by Noetik to Develop Immuno-Oncology Drugs NOETIK an AI drug discovery company leveraging spatial data to develop precision therapeutics in #immunooncology, launched with $14M seed financing. Read more: ow.ly/Me7150PK4Ib

Thrilled to be partnered with Dylan Reid and Zetta Ventures on NOETIK seed. Check out this great piece by Dylan: zettavp.com/articles/why-w…

Wow Yubin Xie just dropped an analysis of 72 million cells, 11,215 tumor cores in slack. LFG.

We just launched our NOETIK Team page at NOETIK.ai - check out the incredible set of folks hard at work launching this ambitious company. We are doctors, scientists, engineers, machine learning researchers, computational biologists, with a shared vision to

After 8 hours staring at tumor genotype-phenotype relationships, its very clear that the future of precision oncology will require more than genomics.

Overnight H&E cut and stain last night. Our histology team is hardcore.

Announcement! NOETIK team are excited to launch a powerful new second(!) platform that connects seamlessly with our human platform to add powerful discovery capabilities... See press release and thread below👇 businesswire.com/news/home/2023…

We are building one of the most significant oncology datasets in the industry, fit for purpose for AI, with seamless connectivity between human data and scaled in vivo functional genomics/pharmacology.

Perturb-map, developed by Icahn Genomics Institute Director Brian Brown, is on the move! NOETIK is pairing their multimodal human data atlas with the innovative in vivo functional genomics platform to power the development of precision cancer immunotherapies: 🧐businesswire.com/news/home/2023…

Unboxing first results from 650 genes in vivo tumor screens vs checkpoint, it’s beautiful.

NOETIK is presenting two posters this Friday at #SITC24! Connect with Lacey Padron for a full stack view of our platform from data to discovery, and Phoebe Guo for exciting work on Tertiary Lymphoid Structure biology. businesswire.com/news/home/2024…

1/ NOETIK team are live at #SITC24 showing off new biological discoveries using our foundation models for human cellular and tissue biology. Come along for a tour: